A5071926023- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Autoimmune and Inflammatory Disorders Research
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Osteoarthritis Treatment and Mechanisms
- Spondyloarthritis Studies and Treatments
- Biosimilars and Bioanalytical Methods
- Lymphoma Diagnosis and Treatment
- Adipokines, Inflammation, and Metabolic Diseases
- Regulation of Appetite and Obesity
- Inflammatory mediators and NSAID effects
- Adipose Tissue and Metabolism
- Psoriasis: Treatment and Pathogenesis
- Immunodeficiency and Autoimmune Disorders
- Cytokine Signaling Pathways and Interactions
- Eosinophilic Disorders and Syndromes
- Tuberculosis Research and Epidemiology
- T-cell and B-cell Immunology
- Infectious Diseases and Tuberculosis
- Systemic Sclerosis and Related Diseases
- Biochemical Analysis and Sensing Techniques
- Toxin Mechanisms and Immunotoxins
- Medical and Biological Sciences
- Viral Infections and Immunology Research
Hospital Clínico Universitario de Valencia
2018-2022
Complejo Hospitalario Universitario de Santiago
2012-2021
Instituto de Investigación Sanitaria de Santiago
2012-2021
Fundación Ramón Domínguez
2015-2021
Fundación Seimc-Gesida
2021
Universidade de Santiago de Compostela
2011-2020
Spanish Society of Hematology and Hemotherapy
2005-2019
Sociedad Española de Reumatología
2017-2018
Servicio Gallego de Salud
2010-2017
Clínica MEDS (Chile)
2017
This criteria set has been approved by the American College of Rheumatology (ACR) Board Directors and European League Against Rheumatism (EULAR) Executive Committee as Provisional.This signifies that quantitatively validated using patient data, but it not undergone validation based on an external data set.All ACR/EULAR-approved sets are expected to undergo intermittent updates.The is independent, professional, medical scientific society which does guarantee, warrant, or endorse any...
The long-term safety of therapeutic agents that neutralize tumor necrosis factor (TNF) is uncertain. Recent evidence based on spontaneous reporting shows an association with active tuberculosis (TB). We undertook this study to determine and describe the 2 these agents, infliximab etanercept, in rheumatic diseases a national active-surveillance system following commercialization drugs.We analyzed data actively collected BIOBADASER (Base de Datos Productos Biológicos la Sociedad Española...
A human antibody to interleukin-17A is well tolerated and may be effective in the treatment of psoriasis, rheumatoid arthritis, noninfectious uveitis.
Abstract Objective To examine the efficacy and safety of humanized anti–interleukin‐6 receptor antibody tocilizumab combined with conventional disease‐modifying antirheumatic drugs (DMARDs) in patients active rheumatoid arthritis (RA). Methods A total 1,220 were randomized (2:1 ratio) phase III, double‐blind, placebo‐controlled, multicenter TOWARD (Tocilizumab Combination With Traditional DMARD Therapy) study. Patients remained on stable doses DMARDs received 8 mg/kg or placebo (control...
Background: The anti-interleukin (IL) 6 receptor antibody tocilizumab inhibits signalling of IL6, a key cytokine in rheumatoid arthritis (RA) pathogenesis. Objective: To evaluate through the AMBITION study efficacy and safety monotherapy versus methotrexate patients with active RA for whom previous treatment methotrexate/biological agents had not failed. Methods: This 24-week, double-blind, double-dummy, parallel-group study, randomised 673 to either 8 mg/kg every 4 weeks, or methotrexate,...
Objective Remission in rheumatoid arthritis (RA) is an increasingly attainable goal, but there no widely used definition of remission that stringent achievable and could be applied uniformly as outcome measure clinical trials. This work was undertaken to develop such a definition. Methods A committee consisting members the American College Rheumatology, European League Against Rheumatism, Outcome Measures Rheumatology Initiative met guide process review prespecified analyses from RA The...
Abstract Objective To investigate the impact of official recommendations regarding management latent tuberculosis (TB) infection on rate active TB in patients receiving treatment with tumor necrosis factor (TNF) antagonists. Methods Data rates and screening were extracted from BIOBADASER (Spanish Society Rheumatology Database Biologic Products), a registry rheumatic conditions treated TNF The among compared those background Spanish population, rheumatoid arthritis (RA) cohort RA EMECAR...
To assess the efficacy and safety of golimumab in patients with active psoriatic arthritis (PsA).Adult PsA who had at least 3 swollen tender joints psoriasis were randomly assigned to receive subcutaneous injections placebo (n = 113), 50 mg 146), or 100 146) every 4 weeks through week 20. Efficacy assessments 24 included American College Rheumatology 20% improvement criteria (ACR20), Psoriasis Area Severity Index (PASI) whom 3% body surface area was affected by baseline, Short Form 36 Health...
<b>Background:</b> Rheumatoid arthritis is a chronic autoimmune inflammatory condition characterised by polyarthritis and severe change in body mass neuroendocrine environment. <b>Objectives:</b> To investigate plasma levels of adipocytokines (leptin, adiponectin, visfatin resistin) patients with rheumatoid to compare them healthy controls. <b>Methods:</b> Adiponectin, resistin, leptin concentrations were measured 31 18 controls using specific enzyme-linked immunosorbent assays....
Anti-tumour necrosis factor (TNF) monoclonal antibodies or soluble TNF receptors have become an invaluable treatment against chronic inflammatory diseases, such as rheumatoid arthritis, bowel disease and psoriasis. Individuals who are treated with antagonists at increased risk of reactivating latent infections, especially tuberculosis (TB). Following antagonist therapy, the relative for TB is up to 25 times, depending on clinical setting used. Interferon-γ release assays or, alternative in...
<h3>Objectives</h3> Apremilast, an oral phosphodiesterase 4 inhibitor, regulates inflammatory mediators. Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) compared apremilast with placebo in patients active psoriatic arthritis despite prior traditional disease-modifying antirheumatic drug (DMARD) and/or biologic therapy. <h3>Methods</h3> In the 24-week, placebo-controlled phase PALACE 1, (N=504) were randomised (1:1:1) to placebo, 20 mg twice a day (BID) or 30 BID....
Abstract Objective To evaluate the causes of new cases active tuberculosis (ATB) in patients treated with tumor necrosis factor (TNF) antagonists included national registry BIOBADASER (Base de Datos Productos Biológicos la Sociedad Española Reumatología) after dissemination recommendations to prevent reactivation latent infection (LTBI). Methods Incidence rate ATB per 100,000 patient‐years and 95% confidence intervals (95% CIs) were calculated entering March 2002 stratified by compliance...
<h3>Objectives:</h3> To assess the efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis (RA) poor prognostic factors. <h3>Methods:</h3> In this double-blind, phase IIIb study, RA for 2 years or less were randomly assigned 1 : to receive (∼10 mg/kg) plus methotrexate, placebo methotrexate. Patients seropositive factor (RF), anti-cyclic citrullinated protein (CCP) type both had radiographic evidence joint erosions. The co-primary endpoints proportion...
Abstract Objective To compare the efficacy, safety, and tolerability of 6 dosages oral tofacitinib (CP‐690,550) with placebo for treatment active rheumatoid arthritis (RA) in patients receiving a stable background regimen methotrexate (MTX) who have an inadequate response to MTX monotherapy. Methods In this 24‐week, double‐blind, phase IIb study, RA (n = 507) were randomized receive or (20 mg/day, 1 mg twice daily, 3 5 10 15 daily). All continued dosage MTX. The primary end point was...
<h3>Background</h3> Biological disease-modifying anti-rheumatic drugs (bioDMARDs) are generally used in combination with conventional synthetic DMARDs (csDMARDs) the treatment of rheumatoid arthritis (RA). Anti-TNF agents more effective csDMARDs (COMBO) than as monotherapy (MONO), while this is debated some newer bioDMARDs.(1) In particular, no difference was found patients (pts) insufficient response to TNF-inhibitors taking abatacept (ABA) MONO vs. COMBO.(2) <h3>Objectives</h3> To compare...